BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 28819868)

  • 21. Impact of Organ-Preserving Strategies on Anorectal Function in Patients with Distal Rectal Cancer Following Neoadjuvant Chemoradiation.
    Habr-Gama A; Lynn PB; Jorge JM; São Julião GP; Proscurshim I; Gama-Rodrigues J; Fernandez LM; Perez RO
    Dis Colon Rectum; 2016 Apr; 59(4):264-9. PubMed ID: 26953984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Magnetic Resonance Tumor Regression Grade and Residual Mucosal Abnormality as Predictors for Pathological Complete Response in Rectal Cancer Postneoadjuvant Chemoradiotherapy.
    Bhoday J; Smith F; Siddiqui MR; Balyasnikova S; Swift RI; Perez R; Habr-Gama A; Brown G
    Dis Colon Rectum; 2016 Oct; 59(10):925-33. PubMed ID: 27602923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of a novel, full-thickness incisional biopsy model to restage rectal tumours after neoadjuvant chemoradiotherapy: results of an ex vivo pilot study.
    Smith FM; Wiland H; Mace A; Pai RK; Kalady MF
    Tech Coloproctol; 2015 Mar; 19(3):159-64. PubMed ID: 25687376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant chemoradiotherapy affects the indications for lateral pelvic node dissection in mid/low rectal cancer with clinically suspected lateral node involvement: a multicenter retrospective cohort study.
    Oh HK; Kang SB; Lee SM; Lee SY; Ihn MH; Kim DW; Park JH; Kim YH; Lee KH; Kim JS; Kim JW; Kim JH; Chang TY; Park SC; Sohn DK; Oh JH; Park JW; Ryoo SB; Jeong SY; Park KJ
    Ann Surg Oncol; 2014 Jul; 21(7):2280-7. PubMed ID: 24604580
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term outcome of local excision after preoperative chemoradiation for ypT0 rectal cancer.
    Stipa F; Picchio M; Burza A; Soricelli E; Vitelli CE
    Dis Colon Rectum; 2014 Nov; 57(11):1245-52. PubMed ID: 25285690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Long-term prognostic analysis on complete/near-complete clinical remission for mid-low rectal cancer after neoadjuvant chemoradiotherapy].
    Wang L; Li S; Zhang X; Sun T; Du C; Chen N; Peng Y; Yao Y; Zhan T; Zhao J; Cai Y; Li Y; Wang W; Li Z; Sun Y; Ji J; Wu A
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Nov; 21(11):1240-1248. PubMed ID: 30506534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Magnetic resonance imaging following neoadjuvant chemoradiation and transanal endoscopic microsurgery for rectal cancer.
    São Julião GP; Ortega CD; Vailati BB; Habr-Gama A; Fernandez LM; Gama-Rodrigues J; Araujo SE; Perez RO
    Colorectal Dis; 2017 Jun; 19(6):O196-O203. PubMed ID: 28436197
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical criteria underestimate complete pathological response in rectal cancer treated with neoadjuvant chemoradiotherapy.
    Smith FM; Wiland H; Mace A; Pai RK; Kalady MF
    Dis Colon Rectum; 2014 Mar; 57(3):311-5. PubMed ID: 24509452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The depth of post-treatment perirectal tissue invasion is a predictor of outcome in patients with clinical T3N1M0 rectal cancer treated with neoadjuvant chemoradiation followed by surgical resection.
    Brandt WS; Yong S; Abood G; Micetich K; Walther A; Shoup M
    Am J Surg; 2014 Mar; 207(3):357-60; discussion 360. PubMed ID: 24456833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can Endorectal Ultrasound, MRI, and Mucosa Integrity Accurately Predict the Complete Response for Mid-Low Rectal Cancer After Preoperative Chemoradiation? A Prospective Observational Study from a Single Medical Center.
    Liu S; Zhong GX; Zhou WX; Xue HD; Pan WD; Xu L; Lu JY; Wu B; Lin GL; Qiu HZ; Xiao Y
    Dis Colon Rectum; 2018 Aug; 61(8):903-910. PubMed ID: 29944579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Application value of colonoscopic assessment in "watch and wait" strategy for mid-lower rectal cancer after neoadjuvant chemoradiotherapy].
    Li SJ; Wang L; Zhang XY; Li YH; Li ZW; Wu Q; Sun YS; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jul; 22(7):648-655. PubMed ID: 31302963
    [No Abstract]   [Full Text] [Related]  

  • 32. Indistinguishable T2/T3-N0 rectal cancer on rectal magnetic resonance imaging: comparison of surgery-first and neoadjuvant chemoradiation therapy-first strategies.
    Kim JG; Song KD; Cha DI; Kim HC; Yu JI
    Int J Colorectal Dis; 2018 Oct; 33(10):1359-1366. PubMed ID: 30003363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extended Intervals after Neoadjuvant Therapy in Locally Advanced Rectal Cancer: The Key to Improved Tumor Response and Potential Organ Preservation.
    Probst CP; Becerra AZ; Aquina CT; Tejani MA; Wexner SD; Garcia-Aguilar J; Remzi FH; Dietz DW; Monson JR; Fleming FJ;
    J Am Coll Surg; 2015 Aug; 221(2):430-40. PubMed ID: 26206642
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Poorer Oncologic Outcome of Good Responders to PCRT With Remnant Lymph Nodes Defies the Oncologic Paradox in Patients With Rectal Cancer.
    Cho E; Park IJ; Hong SM; Lee JL; Kim CW; Yoon YS; Lim SB; Yu CS; Kim JC
    Clin Colorectal Cancer; 2019 Jun; 18(2):e171-e178. PubMed ID: 31027968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer.
    Al-Sukhni E; Attwood K; Mattson DM; Gabriel E; Nurkin SJ
    Ann Surg Oncol; 2016 Apr; 23(4):1177-86. PubMed ID: 26668083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive Factors for Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer.
    Zhang Q; Liang J; Chen J; Mei S; Wang Z
    Asian Pac J Cancer Prev; 2021 May; 22(5):1607-1611. PubMed ID: 34048192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pathologic Complete Response in Rectal Cancer: Can We Detect It? Lessons Learned From a Proposed Randomized Trial of Watch-and-Wait Treatment of Rectal Cancer.
    Nahas SC; Rizkallah Nahas CS; Sparapan Marques CF; Ribeiro U; Cotti GC; Imperiale AR; Capareli FC; Chih Chen AT; Hoff PM; Cecconello I
    Dis Colon Rectum; 2016 Apr; 59(4):255-63. PubMed ID: 26953983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer.
    Gavioli M; Luppi G; Losi L; Bertolini F; Santantonio M; Falchi AM; D'Amico R; Conte PF; Natalini G
    Dis Colon Rectum; 2005 Oct; 48(10):1851-7. PubMed ID: 16132481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy.
    Agarwal A; Chang GJ; Hu CY; Taggart M; Rashid A; Park IJ; You YN; Das P; Krishnan S; Crane CH; Rodriguez-Bigas M; Skibber J; Ellis L; Eng C; Kopetz S; Maru DM
    Cancer; 2013 Dec; 119(24):4231-41. PubMed ID: 24089344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transanal local excision for distal rectal cancer and incomplete response to neoadjuvant chemoradiation - does baseline staging matter?
    Perez RO; Habr-Gama A; São Julião GP; Proscurshim I; Coelho AQ; Figueiredo MN; Fernandez LM; Gama-Rodrigues J
    Dis Colon Rectum; 2014 Nov; 57(11):1253-9. PubMed ID: 25285691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.